|Table of Contents|

Efficacy and safety of raltitrexed combined with oxaliplatin in the second-line chemotherapy of advanced gastric cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2018 01
Page:
80-84
Research Field:
Publishing date:

Info

Title:
Efficacy and safety of raltitrexed combined with oxaliplatin in the second-line chemotherapy of advanced gastric cancer
Author(s):
Zhang ZhiShen JianYu Qingli
Department of Medical Oncology,Baoying People's Hospital of Jiangsu,Jiangsu Baoying 225800,China.
Keywords:
raltitrexedoxaliplatinadvanced gastric carcinomasecond-line chemotherapy
PACS:
R735.2
DOI:
10.3969/j.issn.1672-4992.2018.01.021
Abstract:
Objective:To explore the efficacy and safety of raltitrexed combined with oxaliplatin in the second-line chemotherapy for advanced gastric cancer.Methods:The data of 30 patients were retrospectively collected derived from patients with pathologically proved advanced gastric cancer who have received second-line chemotherapy in Baoying People's Hospital during the period from January 2010 to October 2015.The treated with raltitrexed combined with oxaliplatin chemotherapy patients as the observation group (15 cases),accept capitabine combined with oxaliplatin chemotherapy patients as control group (15 cases),analysis the curative effect and adverse reaction between the two groups.Results:In observation group,CR 0 case,PR 3 cases,SD 8 cases,PD 4 cases,DCR was 73.33%,ORR was 20%.In control group CR 0 case,PR 2 cases,SD 8 cases,PD 5 cases,DCR was 66.67%.ORR was 13.33%.The median PFS was 3.91 months and 3.72 months,OS was 8.07 months and 6.48 months in observation group and control group.Two groups of the main adverse reactions of the white blood cells and neutropenia,nausea,vomiting,transaminase lifts had no statistical differences.Conclusion:For the second-line chemotherapy of advanced gastric cancer patients,raltitrexed combined with oxaliplatin treatmet can achieve efficacy,side effects can be tolerated,which has a broad prospect in clinical treatment.

References:

[1]Kang JH,Lee SI,Lim DH,et al.Salvage chemotherapy for pretreated gastric cancer:a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone[J].J Clin Oncol,2012,30(13):1513-1518.
[2]Zhang Xian,Zhang Yang.Adjuvant chemotherapy for gastric cancer:choice and use[J].Medicine and Philosophy(Clinical Decisitm Making Fom Edition),2011,32(10):18-19.[张弦,张阳.胃癌辅助化疗的选择和应用[J].医学与哲学:临床决策论坛版,2011,32(10):18-19.]
[3]Thuss-Patience PC,Kretzschmar A,Bichev D,et al.Survival advantage for irinotecan versus best supportive care second-line chemotherapy in gastric cancer a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie(AIO)[J].Eur J Cancer,2011,47(15):2306-2314.
[4]Bang YJ,Van Cutsem E,Feyereislova A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (TOGA):a phase 3,open-label,randomized controlled trial[J].Lancet,2010,376(9742):687-697.
[5]Mrklic I,Bendic A,Kunac N,et al.Her-2/neu assessment for gastric carcinoma:validation of scoring system[J].Hepato-gastroenterology,2012,59(13):300-303.
[6]Yue S,Zhang D,Zhou L,et al.Clinical efficacy of raltitrexed combined with docetaxel for advanced gastric cacinoma[J].Cancer Res Preve Treat,2014,41(2):160-162.
[7]Lv Huilai,Wen Shiwang,Li Yong,et al.Clinical observation of raltitrexed with oxaliplantin in treatment of advanced gastric cardial carcinoma[J].Modern Oncology,2016,24(4):555-558.[吕会来,温士旺,李勇,等.雷替曲塞联合奥沙利铂治疗晚期贲门癌的疗效[J].现代肿瘤医学,2016,24(4):555-558.]
[8]Zhao P,Ding Z,Tang L,et al. Preliminary investigation of intraperitoneal raltitrexed in patients with gastric cancer[J].World J Surg Oncol,2014,12(1):403.
[9]Xue S,Chen YX,Qin SK,et al.Raltitrexed induces mitochondrialmediated apoptosis in SGC7901 human gastric cancer cells[J]. Mol Med Rep,2014,10(4):1927-1934.
[10]Hong Lei,Li Hua,Chang Liang,et al.Effects and mechanisms of raltitrexed on the growth of human gastric cancer xenograft transplanted in nude mice[J].Chinese J Clinical Oncology,2014,41(12):766-770.[洪雷,李华,常靓,等.雷替曲塞对人胃癌裸鼠移植瘤生长的影响及其机制[J].中国肿瘤临床,2014,41(12):766-770.]
[11]Feng Li.Clinical effect observation of raltitrexed plus oxaliplatin in treatment of advanced colorectal carcinoma[J].Clinical Misdiagnosis & Mistherapy,2012,25(2):43-46.[冯力.雷替曲塞联合奥沙利铂治疗晚期结直肠癌临床效果观察[J].临床误诊误治,2012,25(2):43-46.]
[12]Zhang Bei.Comparison of the combined raltitrexed-oxaliplatin and combined xeloda-oxaliplatin in the treatment of senile advanced colorectal carcinoma[J].J Clinical Medicine in Practice,2012,16(19):99-101.[张蓓.雷替曲塞与卡培他滨联合奥沙利铂治疗老年晚期结直肠癌的疗效比较[J].实用临床医药杂志,2012,16(19):99-101.]
[13]Ning Chang,Wang Yang,Wang Zhigang,et al.Raltitrexed plus oxaliplatinl in treatment of senile advanced colorectal carcinoma[J].Hainan Medical Journa,2011,22(10):61-63.[宁昌,王洋,王志刚,等.雷替曲塞治疗老年晚期结直肠癌21例临床观察[J].海南医学,2011,22(10):61-63.]
[14]Gravalos C,Salut A,Garcia-Giron C,et al.A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin(FOLFOX4) versus oxaliplatin plus raltitrexed(TOMOX) as first-line chemotherapy for advanced colorectal cancer[J].Clin Transl Oncol,2012,14(8):606-612.
[15]Gao Lidong,Wu Hongwei.Clinical observation of the combination of ray and paclitaxel in the treatment of advanced gastric cancer[J].Modern J Integrated Traditional Chinese and Western Medicine,2013,22(18):2013-2014.[高立冬,吴红卫.雷替曲塞联合紫杉醇一线治疗晚期胃癌的临床观察[J].现代中西医结合杂志,2013,22(18):2013-2014.]
[16]Sun Jing,Sheng Liejie.Clinical observation of raltitrexed combined with docetaxel in the treatment of advanced gastric cancer[J].Modern J Integrated Traditional Chinese and Western Medicine,2013,22(22):2435-3438.[孙静,胜烈杰.雷替曲塞联合多西他赛治疗进展期胃癌的临床观察[J].现代中西医结合杂志,2013,22(22):2435-3438.]
[17]Huo Dan,Zhang Xiaoli.Clinical research of raltitrexed combined docetaxel treatment of advanced gastric cancer[J].Modern Medcine J China,2011,13(10):27-29.[霍丹,张小丽.雷替曲塞联合多西他赛治疗晚期胃癌的临床研究[J].中国现代医药杂志,2011,13(10):27-29.]
[18]Bian Weigang,Song Shu,Shao Weiwei,et al.Raltitrexed combined with oxaliplatin and 5-fluorouracil combined with cisplatin in the treatment of advanced gastric cancer clinical observation[J].J Clinical Internal Medicine,2013,30(12):839-848.[卞伟钢,宋曙,邵伟伟,等.雷替曲塞联合奥沙利铂与5-氟尿嘧啶联合顺铂方案治疗晚期胃癌的临床观察[J].临床内科杂志,2013,30(12):839-848.]
[19]Song Min.Clinical study of raltitrexed combined with oxaliplatin in the treatment of advanced gastric cancer[J].China Health Standard Management,2014,5(3):30-31.[宋敏.雷替曲塞联合奥沙利铂治疗晚期胃癌的临床研究[J].中国卫生标准管理,2014,5(3):30-31.]
[20]Casaretto L,Sousa PLR,Mari JJ.Chemotherapy versus support cancer treatment in advanced gastric carcinoma:a meta-analysis[J].Braz J Med Biol Res,2006,39(4):431-440
[21]He Y,Peng YZ,Ji ZN.Clinical study of oxaliplatin plus raltitrexed versus oxaliplatin plus fluorouracil as first-line treatment for advanced gastric cancer[J].Chin J Clin Pharm Ther,2015,20(2):194-198.
[22]Schmid KF,Kornek GV,Schull B,et al.Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed[J].Onkologie,2003,26(3):255-258.

Memo

Memo:
-
Last Update: 2017-11-30